1. Retrospective review of old patients * Analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015 2. Prospective case-control study: RNA sequencing \& miRNA microarray * naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy * acquirement of tissue, blood, clinical information * isolation of RNA, DNA, serum database of clinical \& demographic information \*\*\*Analysis of mRNA sequencing / miRNA sequencing\*\*\*\* first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator 3. Experimental set for qPCR (esophageal tissue) study group 4. TMA for screened exon gene 5. validation set for qPCR (esophageal tissue) 6. follow-up of circulating miRNA in blood (baseline blood \& post-CCRT blood 3M, 6M, 12M) 7. Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors 8. Validate the prediction model.
1. Retrospective review of old patients * Analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015 Study Group 1. non responder 2. CR but recurrence 3. CR and survival loner than 2 years 2. Prospective case-control study: RNA sequencing \& miRNA microarray * naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy --\> acquirement of tissue, blood, clinical information --\> isolation of RNA, DNA, serum database of clinical \& demographic information study group 1. non-responder (N=14) 2. Complete Remission (N=14) For considering the drop rate, 2-fold screening \*\*\*Analysis of mRNA sequencing / miRNA sequencing\*\*\*\* first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator 3\) Experimental set for qPCR (esophageal tissue) study group 1. non-responder (N=40) 2. complete remission (N=40) 4\) TMA for screened exon gene 5\) validation set for qPCR (esophageal tissue) new esophageal cancer set 1. non-responder (N=30) 2. complete remission (N=30) 6\) follow-up of circulating miRNA in blood (baseline blood \& post-CCRT blood 3M, 6M, 12M) 7\) Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors Test several combination models 1. gene + gene combination, 2. gene + clinical information combination, 3. gene + gene + clinical information combination 8\) Validate the prediction model. 9\) primary organoid culture and prediction of chemoradiotherapy response
Study Type
OBSERVATIONAL
Enrollment
140
concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
Kyungpook National University Medical Canter
Daegu, South Korea
RECRUITINGPrediction model for CCRT response based on clinical and genetic molecular factors
prediction model for CCRT response based on clinical and genetic molecular factors in esophageal cancer
Time frame: up to 36 months
banking of remained human material for post genetic & molecular study
banking of remained human material for post genetic \& molecular study
Time frame: up to 10 years
circulating preditction marker for CCRT response and prognosis
circulating miRNA sequencing
Time frame: up to 5 years
tissue prediction marker for CCRT response and prognosis
tissue RNA sequencing / tissue microarray
Time frame: up to 5 years
in-vitro prediction of CCRT using primary esophageal cancer organoid
1. Esophageal cancer derived primary organoid culture 2. treat RT and 5-FU to esophageal cancer organoid 3. measure the response of CCRT (live cell/dead cell) * This process is in-vitro process, not in-vivo experiment.
Time frame: up to 6 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.